https://www.vernalis.com/successes-in-daiichi-sankyo-collaboration/2024-04-23T13:52:08+00:00https://www.vernalis.com/ligand-anounces-the-close-of-its-acquisition-of-vernalis/2024-04-23T13:52:13+00:00https://www.vernalis.com/vernalis-plc-enters-into-research-collaboration-with-daiichi-sankyo/2024-04-23T13:52:59+00:00https://www.vernalis.com/vernalis-and-servier-achieve-research-milestone-in-third-oncology-collaboration/2024-04-23T13:53:09+00:00https://www.vernalis.com/results-announcement-for-the-year-ended-30-june-2017/2024-04-23T13:37:27+00:00https://www.vernalis.com/year-end-trading-update-and-notice-of-full-year-results/2024-04-23T13:37:17+00:00https://www.vernalis.com/servier-and-vernalis-plc-announce-achievement-of-3-milestones-in-their-oncology-drug-discovery-collaboration/2024-04-23T13:53:53+00:00https://www.vernalis.com/vernalis-plc-receives-a-2-million-milestone-payment-from-one-of-its-drug-discovery-collaborations/2024-04-23T13:49:40+00:00https://www.vernalis.com/vernalis-plc-and-servier-enter-into-a-new-drug-discovery-collaboration-strengthening-their-existing-partnership/2024-04-23T13:50:00+00:00https://www.vernalis.com/unaudited-interim-results-for-the-six-months-ended-31-december-2016/2024-04-23T13:54:05+00:00https://www.vernalis.com/vernalis-achieves-a-3-million-milestone-payment-from-corvus-pharmaceuticals-inc/2024-06-11T10:46:07+00:00https://www.vernalis.com/notice-of-results-for-the-six-months-ended-31-december-2016/2024-04-23T13:54:15+00:00https://www.vernalis.com/fda-accepts-ccp-08-nda-for-full-review/2024-04-23T13:54:15+00:00https://www.vernalis.com/agm-statement/2024-04-23T13:54:24+00:00https://www.vernalis.com/results-announcement-for-the-12-months-ended-30-june-2016/2024-04-23T13:54:39+00:00https://www.vernalis.com/vernalis-achieves-a-milestone-in-its-oncology-collaboration-with-servier/2024-04-23T13:54:47+00:00https://www.vernalis.com/vernalis-notes-the-acquisition-of-redoxtherapies-by-juno-therapeutics/2024-04-23T13:54:55+00:00https://www.vernalis.com/vernalis-announces-successful-completion-of-ccp-08-pivotal-multiple-dose-comparative-bioavailability-study/2024-04-23T13:55:12+00:00https://www.vernalis.com/year-end-trading-update-and-notice-of-results/2024-04-23T13:55:04+00:00https://www.vernalis.com/unaudited-interim-results-announcement-for-the-six-months-ended-31-december-2015/2024-04-23T13:55:20+00:00https://www.vernalis.com/vernalis-announces-corvus-pharmaceuticals-inc-as-its-worldwide-licensee-for-their-adenosine-antagonist-program/2024-04-23T13:55:28+00:00https://www.vernalis.com/vernalis-announces-start-of-ccp-08-12-month-stability-testing/2024-04-23T13:55:35+00:00https://www.vernalis.com/vernalis-plc-acquires-us-rights-to-moxatag/2024-04-23T13:57:03+00:00https://www.vernalis.com/results-announcement-for-the-18-months-ended-30-june-2015/2024-04-23T13:57:13+00:00https://www.vernalis.com/vernalis-plc-launches-tuzistra-xr-codeine-polistirex-and-chlorpheniramine-polistirex-for-cough-relief-with-12-hour-dosing/2024-04-23T13:59:24+00:00https://www.vernalis.com/vernalis-plc-completes-investment-in-its-nce-development-pipeline/2024-04-23T13:59:56+00:00https://www.vernalis.com/vernalis-plc-appointment-of-non-executive-director/2024-04-23T14:00:47+00:00https://www.vernalis.com/vernalis-plc-appointment-of-non-executive-director-2/2024-04-23T14:00:47+00:00https://www.vernalis.com/vernalis-announces-ccp-07-starts-12-month-stability-testing/2024-04-23T14:00:57+00:00https://www.vernalis.com/vernalis-and-tris-pharma-receive-fda-approval-of-nda-for-tuzistra-xr-codeine-polistirex-and-chlorpheniramine-polistirex/2024-04-23T14:00:57+00:00https://www.vernalis.com/vernalis-plc-enters-into-research-collaboration-with-taisho-pharmaceutical-co-ltd/2024-04-23T14:01:08+00:00https://www.vernalis.com/vernalis-and-asahi-kasei-pharma-achieve-research-milestone/2024-04-23T14:01:09+00:00https://www.vernalis.com/vernalis-licenses-proprietary-adenosine-receptor-antagonist-technology-including-lead-compound-v81444-for-development-and-commercialisation/2024-04-23T14:01:18+00:00https://www.vernalis.com/unaudited-interim-results-for-the-periods-ended-31-december-2014/2024-04-23T14:01:28+00:00https://www.vernalis.com/vernalis-licenses-v2006-to-redoxtherapies-inc-for-use-in-immuno-oncology/2024-04-23T14:01:38+00:00https://www.vernalis.com/interim-results-for-the-six-months-ended-30-june-2014/2024-04-23T14:01:38+00:00https://www.vernalis.com/vernalis-and-servier-achieve-two-research-milestones-in-their-oncology-collaborations/2024-04-23T14:02:11+00:00https://www.vernalis.com/vernalis-and-servier-achieve-research-milestone-as-bcl-2-inhibitor-drug-candidate-enters-phase-i/2024-06-11T10:46:44+00:00https://www.vernalis.com/promising-results-of-phase-ib-ii-proof-of-concept-study-in-attention-deficit-hyperactivity-disorder-adhd-with-v81444/2024-04-23T14:02:22+00:00https://www.vernalis.com/vernalis-research-wins-queens-award-for-enterprise/2024-04-23T14:02:33+00:00https://www.vernalis.com/announcement-of-results-for-the-year-ended-31-december-2013/2024-04-23T14:02:33+00:00https://www.vernalis.com/vernalis-and-asahi-kasei-pharma-achieve-research-milestone-2/2024-04-23T14:02:41+00:00https://www.vernalis.com/notice-of-results-for-the-twelve-months-ended-31-december-2013/2024-04-23T14:03:16+00:00https://www.vernalis.com/success-milestone-in-collaboration-with-asahi-kasei-pharma/2024-04-23T13:52:03+00:00https://www.vernalis.com/ligand-licenses-ver250840-to-cumulus-oncology/2019-05-17T13:33:28+00:00https://www.vernalis.com/ligand-subsidiary-vernalis-and-phoremost-limited-announce-drug-discovery-collaboration-for-novel-oncology-target/2019-06-12T13:00:41+00:00https://www.vernalis.com/interview-with-james-murray-research-director-at-vernalis/2019-09-19T11:50:29+00:00https://www.vernalis.com/success-milestone-in-oncology-collaboration-with-servier/2020-02-12T08:24:59+00:00https://www.vernalis.com/ligand-provides-a-corporate-update-and-announces-may-6th-as-the-date-for-first-quarter-earnings-call/2020-04-06T16:46:55+00:00https://www.vernalis.com/ligand-announces-an-expansion-of-vernalis-collaboration-with-servier-for-research-on-novel-oncology-targets/2020-06-15T12:32:38+00:00https://www.vernalis.com/vernalis-and-diamond-turbocharge-structure-based-optimization-of-compounds/2020-09-02T15:56:09+00:00https://www.vernalis.com/hitgen-to-acquire-vernalis-a-leader-in-structure-based-drug-discovery/2020-10-12T10:09:56+00:00https://www.vernalis.com/ligand-to-divest-vernalis-research-operations/2020-10-12T00:45:24+00:00https://www.vernalis.com/vernalis-and-servier-achieve-two-milestones-in-their-oncology-drug-discovery-collaboration/2021-06-10T06:00:07+00:00https://www.vernalis.com/vernalis-a-fully-owned-subsidiary-of-hitgen-inc-and-servier-achieve-a-milestone-in-their-oncology-drug-discovery-collaboration/2021-09-30T06:00:47+00:00https://www.vernalis.com/vernalis-research-a-fully-owned-subsidiary-of-hitgen-inc-and-hannibal-innovation-announce-the-creation-of-dania-therapeutics-aps/2021-11-01T02:00:00+00:00https://www.vernalis.com/vernalis-research-a-fully-owned-subsidiary-of-hitgen-inc-and-unison-medicines-inc-announce-a-research-collaboration-in-the-field-of-anti-infectives/2022-09-05T08:00:08+00:00https://www.vernalis.com/vernalis-research-a-fully-owned-subsidiary-of-hitgen-inc-and-contera-pharma-a-s-announce-a-strategic-collaboration-in-the-field-of-rna-targeting-small-molecules-in-neurology/2022-09-27T12:30:43+00:00https://www.vernalis.com/pierre-fabre-laboratories-and-vernalis-announce-a-drug-discovery-collaboration-in-oncology/2023-09-25T07:25:32+00:00https://www.vernalis.com/venture-forces-invest-millions-in-new-type-of-treatment-for-particularly-aggressive-form-of-cancer/2024-04-30T13:09:27+00:00https://www.vernalis.com/hox-therapeutics-and-vernalis-announce-a-drug-discovery-collaboration-in-oncology/2024-04-30T13:04:02+00:00https://www.vernalis.com/c4x-discovery-and-vernalis-announce-a-drug-discovery-collaboration-in-inflammatory-disease/2024-05-16T07:27:50+00:00https://www.vernalis.com/ihi-project-ligand-ai-launches-to-advance-artificial-intelligence-ai-driven-drug-discovery-through-open-science/2026-03-23T12:38:11+00:00